IPO candidate

Singapore health group moves to US & targets IPO by 2023

Biofourmis, which uses bio-sensor technology and personalised predictive analytics, is moving to Boston after raising another $35 million. Next stop IPO.

Carol Huang

May 23, 2019

Having completed a $35 million Series-B round of fundraising, Singapore's Biofourmis is moving Stateside, the digital therapeutics startup said on Tuesday.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Startups
Southeast Asia
Equity

#biofourmis
#capital raising
#startup
#singapore
#us
#asia
#series b